Literature DB >> 3485133

In vitro production of interleukin 1 by normal and malignant human B lymphocytes.

V Pistoia, F Cozzolino, A Rubartelli, M Torcia, S Roncella, M Ferrarini.   

Abstract

In this study, the capacity of normal and neoplastic B lymphocytes to release interleukin 1 (IL 1) has been investigated. Peripheral blood B cells from normal donors were isolated by depletion of E rosetting cells and by positive selection of cells expressing surface immunoglobulin (sIg) or the B1 marker. Peripheral blood B cells from patients with B cell chronic lymphocytic leukemia (B-CLL) were purified by removal of E rosetting cells followed by complement-mediated cytotoxicity with selected monoclonal antibodies. All of the normal B cell suspensions and the large majority of the B-CLL cells produced in culture high amounts of IL 1 in the absence of any apparent stimulus. Control experiments ruled out that small numbers of monocytes in the B cell suspensions could represent the source of IL 1. These data support the contention that B cells participate to the immune response as accessory cells for T cell activation not only by physically presenting antigen, but also by releasing IL 1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  B cells as under-appreciated mediators of non-auto-immune inflammatory disease.

Authors:  Barbara S Nikolajczyk
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

2.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells.

Authors:  T Yoshimoto; H Okamura; Y I Tagawa; Y Iwakura; K Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.

Authors:  M Aguilar-Santelises; R Magnusson; S B Svenson; A Loftenius; B Andersson; H Mellstedt; M Jondal
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1.

Authors:  B A Blazar; A M Murphy
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

5.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

6.  Mucosal Inducible NO Synthase-Producing IgA+ Plasma Cells in Helicobacter pylori-Infected Patients.

Authors:  Laura Neumann; Mattea Mueller; Verena Moos; Frank Heller; Thomas F Meyer; Christoph Loddenkemper; Christian Bojarski; Michael Fehlings; Thomas Doerner; Kristina Allers; Toni Aebischer; Ralf Ignatius; Thomas Schneider
Journal:  J Immunol       Date:  2016-07-25       Impact factor: 5.422

7.  Induction of murine interleukin 1: stimuli and responsive primary cells.

Authors:  S Koide; R M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 8.  The biological activities of interleukin-1.

Authors:  W E Fibbe; M R Schaafsma; J H Falkenburg; R Willemze
Journal:  Blut       Date:  1989-08

9.  Immunoregulatory functions of paf-acether. VI. Dual effect on human B cell proliferation.

Authors:  C Leprince; E Vivier; D Treton; P Galanaud; J Benveniste; Y Richard; Y Thomas
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

10.  Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells.

Authors:  T Mainou-Fowler; J A Copplestone; A G Prentice
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.